Author Interviews, ESMO, Pharmacology / 09.10.2016
Physicians Should Be Critical of Adverse Event Reporting in Clinical Trials
MedicalResearch.com Interview with:
Paolo Bossi MD
Medical Oncologist
Head and Neck Cancer Department
IRCCS Istituto Nazionale dei Tumori Foundation
Milan, Italy
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Precise, clear and unbiased reporting of adverse events (AE) is essential to ensure safety of the new drugs.
It is crucial also in engaging patients and physicians in a shared decision making: before starting a new treatment I need to discuss with my pt what are the expected benefits and what the toxicities of a new drugs.
However, in parallel to the discovery and development of new drugs, little attention has been paid to modernization of the way of collecting toxicities.
This line of reasoning is particularly true for new or "relatively new" drugs, such as immunotherapy (IT) and targeted agents (TT).
So, we analysed all the trials that lead to the approval of TT or IT from 2000 – 2015 retrieved by FDA database.
(more…)